| Year |
Citation |
Score |
| 2023 |
Nemani K, Goff DC. Dose Finding for d-Serine Enhancement of Plasticity in Schizophrenia. Biological Psychiatry. 94: 106-107. PMID 37380254 DOI: 10.1016/j.biopsych.2023.04.022 |
0.362 |
|
| 2023 |
Miller BJ, Lemos H, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Kane JM, Rapaport MH, et al. Longitudinal study of inflammation and relapse in schizophrenia. Schizophrenia Research. 252: 88-95. PMID 36634452 DOI: 10.1016/j.schres.2022.12.028 |
0.427 |
|
| 2022 |
Qi W, Marx J, Zingman M, Li Y, Petkova E, Blessing E, Ardekani B, Sakalli Kani A, Cather C, Freudenreich O, Holt D, Zhao J, Wang J, Goff DC. Hippocampal Subfield Volumes Predict Disengagement from Maintenance Treatment in First Episode Schizophrenia. Schizophrenia Bulletin. PMID 36370124 DOI: 10.1093/schbul/sbac043 |
0.322 |
|
| 2021 |
Tuominen L, Romaniuk L, Milad MR, Goff DC, Hall J, Holt DJ. Impairment in acquisition of conditioned fear in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 34588608 DOI: 10.1038/s41386-021-01193-1 |
0.366 |
|
| 2021 |
Wang J, Hart KL, Qi W, Ardekani BA, Li C, Marx J, Freudenreich O, Cather C, Holt D, Bello I, Diminich ED, Tang Y, Worthington M, Zeng B, Wu R, ... ... Goff DC, et al. Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia. Journal of Clinical Psychopharmacology. PMID 33814546 DOI: 10.1097/JCP.0000000000001391 |
0.388 |
|
| 2021 |
Goff DC. The Pharmacologic Treatment of Schizophrenia-2021. Jama. 325: 175-176. PMID 33369626 DOI: 10.1001/jama.2020.19048 |
0.425 |
|
| 2020 |
Su W, Zhu T, Xu L, Wei Y, Zeng B, Zhang T, Cui H, Wang J, Jia Y, Wang J, Goff DC, Tang Y, Wang J. Effect of DAOA genetic variation on white matter alteration in corpus callosum in patients with first-episode schizophrenia. Brain Imaging and Behavior. PMID 32748316 DOI: 10.1007/S11682-020-00368-6 |
0.501 |
|
| 2020 |
Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, et al. Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. The Journal of Clinical Psychiatry. 81. PMID 32433836 DOI: 10.4088/Jcp.19Cs13169 |
0.332 |
|
| 2020 |
Kantrowitz JT, Grinband J, Goff DC, Lahti AC, Marder SR, Kegeles LS, Girgis RR, Sobeih T, Wall MM, Choo TH, Green MF, Yang YS, Lee J, Horga G, Krystal JH, et al. Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32403118 DOI: 10.1038/S41386-020-0706-Z |
0.398 |
|
| 2020 |
Goff DC. Promising Evidence of Antipsychotic Efficacy without Dopamine D2-Receptor Binding. The New England Journal of Medicine. 382: 1555-1556. PMID 32294351 DOI: 10.1056/Nejme2001508 |
0.324 |
|
| 2020 |
Goff DC, Li C, Thorpe L. Does Early Intervention Improve the Long-Term Course of Schizophrenia? The American Journal of Psychiatry. appiajp202020020111. PMID 32126809 DOI: 10.1176/Appi.Ajp.2020.20020111 |
0.424 |
|
| 2020 |
Guo Q, Hu Y, Zeng B, Tang Y, Li G, Zhang T, Wang J, Northoff G, Li C, Goff D, Wang J, Yang Z. Parietal memory network and default mode network in first-episode drug-naïve schizophrenia: Associations with auditory hallucination. Human Brain Mapping. PMID 32112506 DOI: 10.1002/Hbm.24923 |
0.402 |
|
| 2020 |
Miller M, Zemon V, Nolan-Kenney R, Balcer LJ, Goff DC, Worthington M, Hasanaj L, Butler PD. Optical coherence tomography of the retina in schizophrenia: Inter-device agreement and relations with perceptual function. Schizophrenia Research. PMID 31937481 DOI: 10.1016/j.schres.2019.10.046 |
0.33 |
|
| 2020 |
Kraus MS, Gold JM, Barch DM, Walker TM, Chun CA, Buchanan RW, Csernansky JG, Goff DC, Green MF, Jarskog LF, Javitt DC, Kimhy D, Lieberman JA, McEvoy JP, Mesholam-Gately RI, et al. The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. Schizophrenia Research. Cognition. 19: 100161. PMID 31832342 DOI: 10.1016/J.Scog.2019.100161 |
0.375 |
|
| 2020 |
Su W, Zhu T, Xu L, Wei Y, Zeng B, Zhang T, Cui H, Wang J, Jia Y, Wang J, Goff DC, Tang Y, Wang J. S171. Effect Of Daoa Genetic Variation On White Matter Alteration In Corpus Callosum In Patients With First-Episode Schizophrenia Schizophrenia Bulletin. 46. DOI: 10.1093/Schbul/Sbaa031.237 |
0.469 |
|
| 2020 |
Gupta PK, Gonen O, Goff D, Bertisch H, Lazar M. Putamen Inflammation and its Association With Working Memory Impairments in Schizophrenia Spectrum Disorders Biological Psychiatry. 87: S213-S214. DOI: 10.1016/J.Biopsych.2020.02.554 |
0.44 |
|
| 2020 |
Qi W, Li C, Blessing E, Ardekani B, Freudenreich O, Cather C, Holt D, Bello I, Diminich E, Tang Y, Worthington M, Zeng B, Wu R, Fan X, Wang J, ... ... Goff DC, et al. Effect of Citalopram on Hippocampal Atrophy in First-Episode Psychosis: Structural MRI Results From the DECIFER Trial Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.439 |
0.309 |
|
| 2020 |
Sui Y, Bertisch H, Goff D, Samsonov A, Lazar M. Changes in Cortical Myelination and Water Volume Fraction With Illness Duration in Schizophrenia Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.397 |
0.432 |
|
| 2020 |
McKenna F, Sui Y, Bertisch H, Goff D, Lazar M. Association Between Gray Matter Microstructure, Cortical Thinning, Illness Duration and Executive Functioning in Psychotic Spectrum Disorders Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.381 |
0.303 |
|
| 2019 |
McKenna F, Babb J, Miles L, Goff D, Lazar M. Reduced Microstructural Lateralization in Males with Chronic Schizophrenia: A Diffusional Kurtosis Imaging Study. Cerebral Cortex (New York, N.Y. : 1991). PMID 31819950 DOI: 10.1093/Cercor/Bhz239 |
0.496 |
|
| 2019 |
McKenna FF, Miles L, Babb JS, Goff DC, Lazar M. Diffusion kurtosis imaging of gray matter in schizophrenia. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior. 121: 201-224. PMID 31629198 DOI: 10.1016/J.Cortex.2019.08.013 |
0.343 |
|
| 2019 |
Blessing EM, Murty VP, Zeng B, Wang J, Davachi L, Goff DC. Anterior Hippocampal-Cortical Functional Connectivity Distinguishes Antipsychotic Naïve First-Episode Psychosis Patients From Controls and May Predict Response to Second-Generation Antipsychotic Treatment. Schizophrenia Bulletin. PMID 31433843 DOI: 10.1093/Schbul/Sbz076 |
0.455 |
|
| 2019 |
Brown HE, Freudenreich O, Fan X, Heard SO, Goff D, Petrides G, Harrington AL, Kane JM, Judge H, Hoeppner B, Fava M, Perlis RH. Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial. Jama Psychiatry. PMID 30916714 DOI: 10.1001/Jamapsychiatry.2019.0151 |
0.42 |
|
| 2019 |
Goff DC. Can Adjunctive Pharmacotherapy Reduce Hospitalization in Schizophrenia?: Insights From Administrative Databases. Jama Psychiatry. PMID 30785617 DOI: 10.1001/jamapsychiatry.2018.4318 |
0.364 |
|
| 2019 |
Fan X, Copeland P, Nawras S, Harrington A, Freudenreich O, Goff DC, Henderson DC. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. Psychopharmacology. PMID 30747254 DOI: 10.1007/s00213-019-5181-z |
0.407 |
|
| 2019 |
Goff DC, Freudenreich O, Cather C, Holt D, Bello I, Diminich E, Tang Y, Ardekani BA, Worthington M, Zeng B, Wu R, Fan X, Li C, Troxel A, Wang J, et al. Citalopram in first episode schizophrenia: The DECIFER trial. Schizophrenia Research. PMID 30709746 DOI: 10.1016/J.Schres.2019.01.028 |
0.302 |
|
| 2019 |
Sui Y, Samsonov A, Bertisch H, Goff D, Lazar M. T186. The Association Between Processing Speed and White Matter Tract Myelination in Schizophrenia Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.509 |
0.419 |
|
| 2019 |
McKenna F, Miles L, Goff D, Lazar M. T179. Executive Function and Microstructural Lateralization Alterations in Schizophrenia Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.502 |
0.468 |
|
| 2019 |
Lieberman J, Goff D, Marder S, Lahti A, Javitt D, Kantrowitz J, Girgis R, Grinband J, Kegeles L, Wall M, Chou T. 117. Biomarker Assessment of Dose Dependent Target Engagement of mGluR-2,3 Partial Agonist for Schizophrenia Treatment Biological Psychiatry. 85: S49. DOI: 10.1016/J.Biopsych.2019.03.131 |
0.458 |
|
| 2018 |
Wang H, Zhang B, Zeng B, Tang Y, Zhang T, Zhao S, Li C, Wang J, Goff DC. Association between catechol-O-methyltransferase genetic variation and functional connectivity in patients with first-episode schizophrenia. Schizophrenia Research. PMID 29730044 DOI: 10.1016/J.Schres.2018.04.023 |
0.436 |
|
| 2018 |
Goff DC, Zeng B, Ardekani BA, Diminich ED, Tang Y, Fan X, Galatzer-Levy I, Li C, Troxel AB, Wang J. Association of Hippocampal Atrophy With Duration of Untreated Psychosis and Molecular Biomarkers During Initial Antipsychotic Treatment of First-Episode Psychosis. Jama Psychiatry. PMID 29466532 DOI: 10.1001/Jamapsychiatry.2017.4595 |
0.471 |
|
| 2017 |
Blokland GAM, Del Re EC, Mesholam-Gately RI, Jovicich J, Trampush JW, Keshavan MS, DeLisi LE, Walters JTR, Turner JA, Malhotra AK, Lencz T, Shenton ME, Voineskos AN, Rujescu D, Giegling I, ... ... Goff DC, et al. The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project. Schizophrenia Research. PMID 28982554 DOI: 10.1016/J.Schres.2017.09.024 |
0.462 |
|
| 2017 |
Fan X, Song X, Zhao M, Jarskog LF, Natarajan R, Shukair N, Freudenreich O, Henderson DC, Goff DC. The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. Acta Psychiatrica Scandinavica. PMID 28851055 DOI: 10.1111/Acps.12799 |
0.519 |
|
| 2017 |
Pillai A, Schooler NR, Peter D, Looney SW, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Kane JM, et al. Predicting relapse in schizophrenia: Is BDNF a plausible biological marker? Schizophrenia Research. PMID 28734907 DOI: 10.1016/J.Schres.2017.06.059 |
0.397 |
|
| 2017 |
Goff DC, Falkai P, Fleischhacker WW, Girgis RR, Kahn RM, Uchida H, Zhao J, Lieberman JA. The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. The American Journal of Psychiatry. appiajp201716091016. PMID 28472900 DOI: 10.1176/Appi.Ajp.2017.16091016 |
0.444 |
|
| 2017 |
Roffman JL, Petruzzi LJ, Tanner AS, Brown HE, Eryilmaz H, Ho NF, Giegold M, Silverstein NJ, Bottiglieri T, Manoach DS, Smoller JW, Henderson DC, Goff DC. Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial. Molecular Psychiatry. PMID 28289280 DOI: 10.1038/Mp.2017.41 |
0.531 |
|
| 2017 |
Levy D, Coleman M, Godfrey L, Morgan C, Sebat J, Ongur D, McCarthy S, Malhotra D, Vuckovic A, Smith K, Kirchhoff C, Suckow R, Coyle J, Rudolph U, Goff D, et al. SU93. Targeted Treatment of a Genetic Mutation in Glycine Decarboxylase With d-Cycloserine in Psychotic Disorders Schizophrenia Bulletin. 43: S194-S195. DOI: 10.1093/Schbul/Sbx024.089 |
0.334 |
|
| 2016 |
Friedman-Yakoobian, Mueser KT, Giuliano AJ, Goff D, Seidman LJ. Family-Directed Cognitive Adaptation Pilot: Teaching Cognitive Adaptation to Families of Individuals with Schizophrenia. American Journal of Psychiatric Rehabilitation. 19: 62-74. PMID 29167630 DOI: 10.1080/15487768.2015.1125401 |
0.316 |
|
| 2016 |
Trémeau F, Antonius D, Malaspina D, Goff DC, Javitt DC. Loneliness in schizophrenia and its possible correlates. An exploratory study. Psychiatry Research. 246: 211-217. PMID 27721059 DOI: 10.1016/J.Psychres.2016.09.043 |
0.458 |
|
| 2016 |
Diminich ED, Goff DC. Is Pupillary Response a Biomarker for Effort and Defeatist Attitudes in Patients With Schizophrenia? Biological Psychiatry. 80: 574-6. PMID 27663064 DOI: 10.1016/J.Biopsych.2016.08.020 |
0.493 |
|
| 2016 |
Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck TC, Mendelowitz A, Miller DD, Wilson DR, Ames D, Bustillo JR, Kane JM, Looney SW. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. Psychiatric Services (Washington, D.C.). appips201500466. PMID 27476806 DOI: 10.1176/Appi.Ps.201500466 |
0.47 |
|
| 2016 |
Eryilmaz H, Tanner AS, Ho NF, Nitenson AZ, Silverstein NJ, Petruzzi LJ, Goff DC, Manoach DS, Roffman JL. Disrupted working Memory Circuitry in Schizophrenia: Disentangling fMRI Markers of Core Pathology Versus other Aspects of Impaired Performance. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 27103065 DOI: 10.1038/Npp.2016.55 |
0.462 |
|
| 2016 |
Goff DC, Romero K, Paul J, Mercedes Perez-Rodriguez M, Crandall D, Potkin SG. Biomarkers for drug development in early psychosis: Current issues and promising directions. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 26: 923-37. PMID 27005595 DOI: 10.1016/J.Euroneuro.2016.01.009 |
0.42 |
|
| 2016 |
Zeng B, Ardekani BA, Tang Y, Zhang T, Zhao S, Cui H, Fan X, Zhuo K, Li C, Xu Y, Goff DC, Wang J. Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment. Schizophrenia Research. PMID 26852402 DOI: 10.1016/j.schres.2016.01.051 |
0.419 |
|
| 2016 |
Manseau MW, Goff DC. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 12: 816-24. PMID 26311150 DOI: 10.1007/s13311-015-0382-6 |
0.437 |
|
| 2015 |
Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA, Mates S, Vanover KE. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. Biological Psychiatry. PMID 26444072 DOI: 10.1016/J.Biopsych.2015.08.026 |
0.492 |
|
| 2015 |
Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D, Carpenter WT, Csernansky JT, Dago PL, Durand DM, ... ... Goff DC, et al. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophrenia Bulletin. PMID 26362273 DOI: 10.1093/Schbul/Sbv111 |
0.359 |
|
| 2015 |
Goff DC. Brexpiprazole: A new antipsychotic following in the footsteps of aripiprazole American Journal of Psychiatry. 172: 820-821. PMID 26324298 DOI: 10.1176/Appi.Ajp.2015.15060741 |
0.348 |
|
| 2015 |
Murck H, Laughren T, Lamers F, Picard R, Walther S, Goff D, Sainati S. Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. Innovations in Clinical Neuroscience. 12: 26S-40S. PMID 25977838 |
0.324 |
|
| 2015 |
Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, et al. A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research. 164: 136-42. PMID 25728831 DOI: 10.1016/J.Schres.2015.01.041 |
0.378 |
|
| 2015 |
Goff DC. Drug development in schizophrenia: are glutamatergic targets still worth aiming at? Current Opinion in Psychiatry. 28: 207-15. PMID 25710242 DOI: 10.1097/YCO.0000000000000152 |
0.332 |
|
| 2015 |
Cohen SM, Tsien RW, Goff DC, Halassa MM. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophrenia Research. PMID 25583246 DOI: 10.1016/J.Schres.2014.12.026 |
0.399 |
|
| 2015 |
Murck H, Laughren T, Lamers F, Picard R, Walther S, Goff D, Sainati S. Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. Innovations in Clinical Neuroscience. 12. DOI: 10.7892/Boris.69085 |
0.433 |
|
| 2015 |
Manseau MW, Goff DC. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential Neurotherapeutics. 12: 816-824. DOI: 10.1007/S13311-015-0382-6 |
0.528 |
|
| 2014 |
Agam Y, Vangel M, Roffman JL, Gallagher PJ, Chaponis J, Haddad S, Goff DC, Greenberg JL, Wilhelm S, Smoller JW, Manoach DS. Dissociable genetic contributions to error processing: a multimodal neuroimaging study. Plos One. 9: e101784. PMID 25010186 DOI: 10.1371/Journal.Pone.0101784 |
0.305 |
|
| 2014 |
Goff DC. Maintenance treatment with long-acting injectable antipsychotics: comparing old with new. Jama. 311: 1973-4. PMID 24846032 DOI: 10.1001/Jama.2014.4311 |
0.437 |
|
| 2014 |
Cain CK, McCue M, Bello I, Creedon T, Tang DI, Laska E, Goff DC. d-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophrenia Research. 153: 177-83. PMID 24485587 DOI: 10.1016/J.Schres.2014.01.016 |
0.461 |
|
| 2014 |
Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, Achtyes ED, Ayer D, Schoenfeld DA. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. Jama. 311: 145-54. PMID 24399553 DOI: 10.1001/Jama.2013.285113 |
0.362 |
|
| 2014 |
Roffman J, Lamberti SJ, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Tanner AS, Silverstein NJ, Ho NF, Smoller JW, Hill M, Goff DC. Effects Of Folic Acid And Vitamin B12 Supplementation On Negative Symptoms And Related Mri Indices Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70259-2 |
0.46 |
|
| 2013 |
Wamsley EJ, Shinn AK, Tucker MA, Ono KE, McKinley SK, Ely AV, Goff DC, Stickgold R, Manoach DS. The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized placebo-controlled trial. Sleep. 36: 1369-76. PMID 23997371 DOI: 10.5665/Sleep.2968 |
0.424 |
|
| 2013 |
Goff DC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, Buckley P, Manschreck TC, Achtyes ED, Macklin EA. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. Journal of Clinical Psychopharmacology. 33: 485-90. PMID 23775057 DOI: 10.1097/Jcp.0B013E3182977308 |
0.424 |
|
| 2013 |
Cather C, Dyer MA, Burrell HA, Hoeppner B, Goff DC, Evins AE. An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia. Journal of Dual Diagnosis. 9: 87-93. PMID 23750123 DOI: 10.1080/15504263.2012.749559 |
0.474 |
|
| 2013 |
Goff DC. Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 12: 99-107. PMID 23737409 DOI: 10.1002/wps.20026 |
0.407 |
|
| 2013 |
Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. Jama Psychiatry. 70: 481-9. PMID 23467813 DOI: 10.1001/Jamapsychiatry.2013.900 |
0.448 |
|
| 2013 |
Li J, Li X, Liu E, Copeland P, Freudenreich O, Goff DC, Henderson DC, Song X, Fan X. No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia. Schizophrenia Research. 146: 40-5. PMID 23434504 DOI: 10.1016/J.Schres.2013.01.034 |
0.443 |
|
| 2013 |
Fan X, Liu E, Freudenreich O, Copeland P, Hayden D, Ghebremichael M, Cohen B, Ongur D, Goff DC, Henderson DC. No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia. Journal of Clinical Psychopharmacology. 33: 226-30. PMID 23422397 DOI: 10.1097/Jcp.0B013E31828701D0 |
0.467 |
|
| 2013 |
Manoach DS, Lee AK, Hämäläinen MS, Dyckman KA, Friedman JS, Vangel M, Goff DC, Barton JJ. Anomalous use of context during task preparation in schizophrenia: a magnetoencephalography study. Biological Psychiatry. 73: 967-75. PMID 23380717 DOI: 10.1016/J.Biopsych.2012.12.018 |
0.477 |
|
| 2013 |
Freudenreich O, Henderson DC, Sanders KM, Goff DC. Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation. Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association For Academic Psychiatry. 37: 27-30. PMID 23338869 DOI: 10.1176/Appi.Ap.11090159 |
0.392 |
|
| 2013 |
Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 1245-52. PMID 23325325 DOI: 10.1038/Npp.2013.23 |
0.5 |
|
| 2013 |
Linnman C, Coombs G, Goff DC, Holt DJ. Lack of insula reactivity to aversive stimuli in schizophrenia. Schizophrenia Research. 143: 150-7. PMID 23201307 DOI: 10.1016/J.Schres.2012.10.038 |
0.487 |
|
| 2013 |
Fan X, Borba CP, Copeland P, Hayden D, Freudenreich O, Goff DC, Henderson DC. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatrica Scandinavica. 127: 217-26. PMID 22943577 DOI: 10.1111/Acps.12009 |
0.5 |
|
| 2013 |
Roffman JL, Brohawn DG, Nitenson AZ, Macklin EA, Smoller JW, Goff DC. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophrenia Bulletin. 39: 330-8. PMID 22021659 DOI: 10.1093/Schbul/Sbr150 |
0.412 |
|
| 2012 |
Holt DJ, Coombs G, Zeidan MA, Goff DC, Milad MR. Failure of neural responses to safety cues in schizophrenia. Archives of General Psychiatry. 69: 893-903. PMID 22945619 DOI: 10.1001/Archgenpsychiatry.2011.2310 |
0.451 |
|
| 2012 |
Pachas GN, Cather C, Pratt SA, Hoeppner B, Nino J, Carlini SV, Achtyes ED, Lando H, Mueser KT, Rigotti NA, Goff DC, Evins AE. Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial. Journal of Dual Diagnosis. 8: 117-125. PMID 22888309 DOI: 10.1080/15504263.2012.663675 |
0.374 |
|
| 2012 |
Yi Z, Fan X, Wang J, Liu D, Freudenreich O, Goff D, Henderson DC. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study. Psychiatry Research. 200: 79-82. PMID 22727707 DOI: 10.1016/J.Psychres.2012.05.020 |
0.499 |
|
| 2012 |
Wang J, Fan X, Liu D, Yi Z, Freudenreich O, Goff D, Henderson DC. Both physical activity and food intake are associated with metabolic risks in patients with schizophrenia. Schizophrenia Research. 140: 260-1. PMID 22682987 DOI: 10.1016/J.Schres.2012.05.008 |
0.404 |
|
| 2012 |
Goff DC. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophrenia Bulletin. 38: 936-41. PMID 22368237 DOI: 10.1093/schbul/sbs012 |
0.325 |
|
| 2012 |
Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia Research. 136: 25-31. PMID 22169248 DOI: 10.1016/J.Schres.2011.11.001 |
0.492 |
|
| 2012 |
Wamsley EJ, Tucker MA, Shinn AK, Ono KE, McKinley SK, Ely AV, Goff DC, Stickgold R, Manoach DS. Reduced sleep spindles and spindle coherence in schizophrenia: mechanisms of impaired memory consolidation? Biological Psychiatry. 71: 154-61. PMID 21967958 DOI: 10.1016/J.Biopsych.2011.08.008 |
0.378 |
|
| 2012 |
Ehrlich S, Yendiki A, Greve DN, Manoach DS, Ho BC, White T, Schulz SC, Goff DC, Gollub RL, Holt DJ. Striatal function in relation to negative symptoms in schizophrenia. Psychological Medicine. 42: 267-82. PMID 21733291 DOI: 10.1017/S003329171100119X |
0.462 |
|
| 2012 |
Balu DT, Goff DC. Schizophrenia Translational Neuroscience: Applications in Psychiatry, Neurology, and Neurodevelopmental Disorders. 80-106. DOI: 10.1017/CBO9780511980053.005 |
0.435 |
|
| 2012 |
Sitnikova T, Gramfort A, Boyle RW, Cather C, Freudenreich O, Hämäläinen MS, Rosen BR, Goff DC. Poster #35 PREFRONTAL CORTEX AND GOAL-DIRECTED BEHAVIOR IN SCHIZOPHRENIA: NEURAL MECHANISMS UNDERLYING INFLEXIBILITY Schizophrenia Research. 136: S104. DOI: 10.1016/S0920-9964(12)70351-1 |
0.425 |
|
| 2012 |
Schooler NR, Kane J, Goff DC. Long Acting Injectable Antipsychotic Medications In Schizophrenia: Do Recent Studies Change Our Understanding Of Their Role In Our Treatment Armamentarium? Schizophrenia Research. 136. DOI: 10.1016/S0920-9964(12)70015-4 |
0.469 |
|
| 2011 |
Brown HE, Flaherty AW, Goff DC, Freudenreich O. A case of dramatic improvement of severe tardive dyskinesia after switch to aripiprazole. The Primary Care Companion For Cns Disorders. 13. PMID 22454797 DOI: 10.4088/Pcc.11L01188 |
0.375 |
|
| 2011 |
Roffman JL, Nitenson AZ, Agam Y, Isom M, Friedman JS, Dyckman KA, Brohawn DG, Smoller JW, Goff DC, Manoach DS. A hypomethylating variant of MTHFR, 677C>T, blunts the neural response to errors in patients with schizophrenia and healthy individuals. Plos One. 6: e25253. PMID 21980405 DOI: 10.1371/Journal.Pone.0025253 |
0.435 |
|
| 2011 |
Dyckman KA, Lee AK, Agam Y, Vangel M, Goff DC, Barton JJ, Manoach DS. Abnormally persistent fMRI activation during antisaccades in schizophrenia: a neural correlate of perseveration? Schizophrenia Research. 132: 62-8. PMID 21831602 DOI: 10.1016/J.Schres.2011.07.026 |
0.526 |
|
| 2011 |
Tranulis C, Goff D, Henderson DC, Freudenreich O. Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients. Psychiatric Services (Washington, D.C.). 62: 888-92. PMID 21807827 DOI: 10.1176/Ps.62.8.Pss6208_0888 |
0.432 |
|
| 2011 |
Goff DC, Dixon L. Antipsychotic polypharmacy: are two ever better than one? The American Journal of Psychiatry. 168: 667-9. PMID 21724670 DOI: 10.1176/Appi.Ajp.2011.11020314 |
0.465 |
|
| 2011 |
Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophrenia Research. 131: 69-74. PMID 21723096 DOI: 10.1016/J.Schres.2011.05.029 |
0.375 |
|
| 2011 |
Henderson DC, Freudenreich O, Borba CP, Wang X, Copeland PM, Macklin E, Fan X, Cather C, Goff DC. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophrenia Research. 130: 53-6. PMID 21565464 DOI: 10.1016/J.Schres.2011.04.009 |
0.447 |
|
| 2011 |
Goff DC, Hill M, Freudenreich O. Treatment adherence in schizophrenia and schizoaffective disorder The Journal of Clinical Psychiatry. 72: e13. PMID 21527119 DOI: 10.4088/Jcp.9096Tx6Cc |
0.402 |
|
| 2011 |
Fan X, Copeland PM, Liu EY, Chiang E, Freudenreich O, Goff DC, Henderson DC. No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia. Journal of Clinical Psychopharmacology. 31: 231-4. PMID 21346605 DOI: 10.1097/Jcp.0B013E31820Ebd0E |
0.508 |
|
| 2011 |
Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC. Folate supplementation in schizophrenia: A possible role for MTHFR genotype Schizophrenia Research. 127: 41-45. PMID 21334854 DOI: 10.1016/J.Schres.2010.12.006 |
0.429 |
|
| 2011 |
Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, Davis S, Stroup TS, Swartz M, Lieberman J, Rosenheck R. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophrenia Research. 128: 166-70. PMID 21334853 DOI: 10.1016/J.Schres.2011.01.022 |
0.421 |
|
| 2011 |
Ditman T, Goff D, Kuperberg GR. Slow and steady: sustained effects of lexico-semantic associations can mediate referential impairments in schizophrenia. Cognitive, Affective & Behavioral Neuroscience. 11: 245-58. PMID 21267802 DOI: 10.3758/S13415-011-0020-7 |
0.426 |
|
| 2011 |
Roffman JL, Brohawn DG, Friedman JS, Dyckman KA, Thakkar KN, Agam Y, Vangel MG, Goff DC, Manoach DS. MTHFR 677C>T effects on anterior cingulate structure and function during response monitoring in schizophrenia: a preliminary study. Brain Imaging and Behavior. 5: 65-75. PMID 21190096 DOI: 10.1007/S11682-010-9111-2 |
0.455 |
|
| 2011 |
Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry. 69: 442-9. PMID 21145041 DOI: 10.1016/J.Biopsych.2010.09.052 |
0.492 |
|
| 2011 |
Holt DJ, Cassidy BS, Andrews-Hanna JR, Lee SM, Coombs G, Goff DC, Gabrieli JD, Moran JM. An anterior-to-posterior shift in midline cortical activity in schizophrenia during self-reflection. Biological Psychiatry. 69: 415-23. PMID 21144498 DOI: 10.1016/J.Biopsych.2010.10.003 |
0.445 |
|
| 2011 |
Goff DC, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacology, Biochemistry, and Behavior. 99: 245-53. PMID 21115035 DOI: 10.1016/J.Pbb.2010.11.009 |
0.431 |
|
| 2011 |
Holt DJ, Lakshmanan B, Freudenreich O, Goff DC, Rauch SL, Kuperberg GR. Dysfunction of a cortical midline network during emotional appraisals in schizophrenia. Schizophrenia Bulletin. 37: 164-76. PMID 19605517 DOI: 10.1093/Schbul/Sbp067 |
0.441 |
|
| 2011 |
Kuperberg GR, Kreher DA, Swain A, Goff DC, Holt DJ. Selective emotional processing deficits to social vignettes in schizophrenia: an ERP study. Schizophrenia Bulletin. 37: 148-63. PMID 19564165 DOI: 10.1093/Schbul/Sbp018 |
0.429 |
|
| 2011 |
Friedman-Yakoobian M, Mueser K, Giuliano A, Bryant C, Goff D, Seidman L. Family directed cognitive adaptation program for individuals with schizophrenia F1000research. 2. DOI: 10.7490/F1000Research.1089282.1 |
0.422 |
|
| 2011 |
Goff D, Cather C, Gottlieb J, Macklin E. The Potential Role for D-cycloserine Facilitation of CBT in Schizophrenia International Clinical Psychopharmacology. 26: e135. DOI: 10.1097/01.Yic.0000405863.45893.11 |
0.484 |
|
| 2010 |
Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder Journal of Clinical Psychiatry. 71: 20-26. PMID 21190649 DOI: 10.4088/Jcp.9096Su1Cc.04 |
0.393 |
|
| 2010 |
Wang J, Liu EY, Freudenreich O, Goff D, Henderson DC, Fan X. Phenotypic characteristics in metabolically obese but normal weight non-diabetic patients with schizophrenia. Schizophrenia Research. 124: 49-53. PMID 20947306 DOI: 10.1016/J.Schres.2010.09.013 |
0.412 |
|
| 2010 |
Fan X, Liu EY, Freudenreich O, Park JH, Liu D, Wang J, Yi Z, Goff D, Henderson DC. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophrenia Research. 118: 211-7. PMID 20189773 DOI: 10.1016/J.Schres.2010.02.1028 |
0.453 |
|
| 2010 |
Tu P, Buckner RL, Zollei L, Dyckman KA, Goff DC, Manoach DS. Reduced functional connectivity in a right-hemisphere network for volitional ocular motor control in schizophrenia. Brain : a Journal of Neurology. 133: 625-37. PMID 20159769 DOI: 10.1093/Brain/Awp317 |
0.395 |
|
| 2010 |
Freudenreich O, Brockman MA, Henderson DC, Evins AE, Fan X, Walsh JP, Goff DC. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Research. 176: 99-102. PMID 20132993 DOI: 10.1016/J.Psychres.2008.11.007 |
0.366 |
|
| 2010 |
Sitnikova T, Perrone C, Goff D, Kuperberg GR. Neurocognitive mechanisms of conceptual processing in healthy adults and patients with schizophrenia. International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology. 75: 86-99. PMID 20004221 DOI: 10.1016/J.Ijpsycho.2009.12.002 |
0.49 |
|
| 2010 |
Manoach DS, Thakkar KN, Stroynowski E, Ely A, McKinley SK, Wamsley E, Djonlagic I, Vangel MG, Goff DC, Stickgold R. Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages. Journal of Psychiatric Research. 44: 112-20. PMID 19665729 DOI: 10.1016/J.Jpsychires.2009.06.011 |
0.343 |
|
| 2010 |
Schulz C, Bustillo J, Lauriello J, Freudenreich O, Goff D, Bockholt J, Lim K. Multimodal Imaging Studies Of Early Stages And Persistent Schizophrenia Schizophrenia Research. 117: 126-127. DOI: 10.1016/J.Schres.2010.02.074 |
0.414 |
|
| 2010 |
Buchanan RW, Barch D, Csernansky J, Goff D, Gold J, Jarskog F, Javitt D, Keefe R, Lieberman J, McEvoy J, McMahon R, Marder S. MK-0777 FOR THE TREATMENT OF COGNITIVE IMPAIRMENTS IN PEOPLE WITH SCHIZOPHRENIA Schizophrenia Research. 117: 119. DOI: 10.1016/J.Schres.2010.02.053 |
0.478 |
|
| 2010 |
Goff DC. Searching For Cognitive Enhancers In Schizophrenia: The Turns Program Strategy Schizophrenia Research. 117: 118-118. DOI: 10.1016/J.Schres.2010.02.051 |
0.449 |
|
| 2009 |
Freudenreich O, Charles Schulz S, Goff DC. Initial medical work-up of first-episode psychosis: A conceptual review Early Intervention in Psychiatry. 3: 10-18. PMID 21352170 DOI: 10.1111/J.1751-7893.2008.00105.X |
0.379 |
|
| 2009 |
Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. The Journal of Clinical Psychiatry. 70: 1348-57. PMID 19906340 DOI: 10.4088/Jcp.09M05154Yel |
0.532 |
|
| 2009 |
Goff DC. Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia. Evidence-Based Mental Health. 12: 111. PMID 19854773 DOI: 10.1136/ebmh.12.4.111 |
0.367 |
|
| 2009 |
Weiss AP, Ellis CB, Roffman JL, Stufflebeam S, Hamalainen MS, Duff M, Goff DC, Schacter DL. Aberrant frontoparietal function during recognition memory in schizophrenia: a multimodal neuroimaging investigation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 11347-59. PMID 19741141 DOI: 10.1523/Jneurosci.0617-09.2009 |
0.421 |
|
| 2009 |
Freudenreich O, Henderson DC, Macklin EA, Evins AE, Fan X, Cather C, Walsh JP, Goff DC. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. The Journal of Clinical Psychiatry. 70: 1674-80. PMID 19689921 DOI: 10.4088/Jcp.08M04683 |
0.526 |
|
| 2009 |
Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, Lieberman JA. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry. 66: 1013-22. PMID 19640511 DOI: 10.1016/J.Biopsych.2009.06.005 |
0.389 |
|
| 2009 |
Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine. Journal of Psychiatric Practice. 15: 251-61. PMID 19625881 DOI: 10.1097/01.Pra.0000358312.99233.Ef |
0.353 |
|
| 2009 |
Friedman-Yakoobian MS, Mueser KT, Giuliano A, Goff DC, Seidman LJ. Family-directed cognitive adaptation for schizophrenia Journal of Clinical Psychology. 65: 854-867. PMID 19536868 DOI: 10.1002/Jclp.20611 |
0.371 |
|
| 2009 |
Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of Clinical Psychopharmacology. 29: 165-9. PMID 19512978 DOI: 10.1097/Jcp.0B013E31819A8Dbe |
0.342 |
|
| 2009 |
Sitnikova T, Goff D, Kuperberg GR. Neurocognitive abnormalities during comprehension of real-world goal-directed behaviors in schizophrenia. Journal of Abnormal Psychology. 118: 256-77. PMID 19413402 DOI: 10.1037/A0015619 |
0.482 |
|
| 2009 |
Kreher DA, Goff D, Kuperberg GR. Why all the confusion? Experimental task explains discrepant semantic priming effects in schizophrenia under "automatic" conditions: evidence from Event-Related Potentials. Schizophrenia Research. 111: 174-81. PMID 19386472 DOI: 10.1016/J.Schres.2009.03.013 |
0.51 |
|
| 2009 |
Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, Miley K, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC. Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Human Psychopharmacology. 24: 225-32. PMID 19283774 DOI: 10.1002/Hup.1012 |
0.458 |
|
| 2009 |
Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, Freudenreich O, Cather C, Eden Evins A, Goff DC. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia Acta Psychiatrica Scandinavica. 119: 457-465. PMID 19183127 DOI: 10.1111/J.1600-0447.2008.01325.X |
0.425 |
|
| 2009 |
Holt DJ, Lebron-Milad K, Milad MR, Rauch SL, Pitman RK, Orr SP, Cassidy BS, Walsh JP, Goff DC. Extinction memory is impaired in schizophrenia. Biological Psychiatry. 65: 455-63. PMID 18986648 DOI: 10.1016/J.Biopsych.2008.09.017 |
0.485 |
|
| 2009 |
Goff DC, Cather C, Freudenreich O, Henderson DC, Evins AE, Culhane MA, Walsh JP. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology. 202: 411-7. PMID 18716761 DOI: 10.1007/S00213-008-1278-5 |
0.413 |
|
| 2008 |
Culhane MA, Schoenfeld DA, Barr RS, Cather C, Deckersbach T, Freudenreich O, Goff DC, Rigotti NA, Evins AE. Predictors of early abstinence in smokers with schizophrenia. The Journal of Clinical Psychiatry. 69: 1743-50. PMID 19026259 DOI: 10.4088/Jcp.V69N1109 |
0.377 |
|
| 2008 |
Roffman JL, Gollub RL, Calhoun VD, Wassink TH, Weiss AP, Ho BC, White T, Clark VP, Fries J, Andreasen NC, Goff DC, Manoach DS. MTHFR 677C --> T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val --> Met. Proceedings of the National Academy of Sciences of the United States of America. 105: 17573-8. PMID 18988738 DOI: 10.1073/Pnas.0803727105 |
0.45 |
|
| 2008 |
Morrow EM, Kane A, Goff DC, Walsh CA. Sequence analysis of P21-activated kinase 3 (PAK3) in chronic schizophrenia with cognitive impairment. Schizophrenia Research. 106: 265-7. PMID 18805672 DOI: 10.1016/J.Schres.2008.08.021 |
0.506 |
|
| 2008 |
Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophrenia Research. 106: 320-7. PMID 18799288 DOI: 10.1016/J.Schres.2008.08.012 |
0.44 |
|
| 2008 |
Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research. 105: 175-87. PMID 18775645 DOI: 10.1016/J.Schres.2008.07.006 |
0.384 |
|
| 2008 |
Evin AE, Goff DC. Varenicline treatment for smokers with schizophrenia: A case series Journal of Clinical Psychiatry. 69: 1016. PMID 18683999 DOI: 10.4088/Jcp.V69N0620A |
0.399 |
|
| 2008 |
Goff DC. New insights into clinical response in schizophrenia: From dopamine D 2 receptor occupancy to patients' quality of life American Journal of Psychiatry. 165: 940-943. PMID 18676595 DOI: 10.1176/Appi.Ajp.2008.08050673 |
0.417 |
|
| 2008 |
Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, Evins AE. Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology. 199: 89-98. PMID 18548234 DOI: 10.1007/S00213-008-1133-8 |
0.452 |
|
| 2008 |
Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophrenia Research. 103: 104-9. PMID 18534821 DOI: 10.1016/J.Schres.2008.04.023 |
0.488 |
|
| 2008 |
Fan X, Henderson DC, Nguyen DD, Cather C, Freudenreich O, Evins AE, Borba CP, Goff DC. Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. Psychiatry Research. 159: 140-6. PMID 18423611 DOI: 10.1016/J.Psychres.2007.10.012 |
0.442 |
|
| 2008 |
Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, Goff DC, Evins AE. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophrenia Research. 102: 88-95. PMID 18325740 DOI: 10.1016/J.Schres.2007.12.491 |
0.502 |
|
| 2008 |
Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophrenia Research. 101: 273-86. PMID 18258416 DOI: 10.1016/J.Schres.2007.12.487 |
0.453 |
|
| 2008 |
Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, Henderson DC, Wong DH, Halsted CH, Goff DC. Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 147: 990-5. PMID 18186041 DOI: 10.1002/Ajmg.B.30684 |
0.459 |
|
| 2008 |
Barton JJ, Pandita M, Thakkar K, Goff DC, Manoach DS. The relation between antisaccade errors, fixation stability and prosaccade errors in schizophrenia. Experimental Brain Research. 186: 273-82. PMID 18057921 DOI: 10.1007/S00221-007-1235-2 |
0.388 |
|
| 2008 |
Kreher DA, Holcomb PJ, Goff D, Kuperberg GR. Neural evidence for faster and further automatic spreading activation in schizophrenic thought disorder. Schizophrenia Bulletin. 34: 473-82. PMID 17905785 DOI: 10.1093/Schbul/Sbm108 |
0.422 |
|
| 2008 |
Weiss AP, Goff DC, Duff M, Roffman JL, Schacter DL. Distinguishing familiarity-based from source-based memory performance in patients with schizophrenia. Schizophrenia Research. 99: 208-17. PMID 17629463 DOI: 10.1016/J.Schres.2007.05.028 |
0.461 |
|
| 2008 |
Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, Bottiglieri T, Wong DH, Halsted CH, Goff DC. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biological Psychiatry. 63: 42-8. PMID 17543893 DOI: 10.1016/J.Biopsych.2006.12.017 |
0.466 |
|
| 2008 |
Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 465-72. PMID 17487227 DOI: 10.1038/Sj.Npp.1301444 |
0.479 |
|
| 2008 |
Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, Deckersbach T, Kelly JF, Freudenreich O, Goff DC, Evins AE. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 480-90. PMID 17443126 DOI: 10.1038/Sj.Npp.1301423 |
0.456 |
|
| 2008 |
Freudenreich O, Tranulis C, Cather C, Henderson DC, Evins AE, Goff DC. Depressive symptoms in schizophrenia outpatients - Prevalence and clinical correlates Clinical Schizophrenia and Related Psychoses. 2: 127-135. DOI: 10.3371/Csrp.2.2.2 |
0.443 |
|
| 2008 |
Correll CU, Kane J, Goff D, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Pikalov A, Assunção-Talbott S. Aripiprazole In Combination With Risperidone Or Quetiapine: Results From A 16-Week, Randomized, Double-Blind Study In Subjects With Schizophrenia Schizophrenia Research. 102: 254. DOI: 10.1016/S0920-9964(08)70764-3 |
0.511 |
|
| 2008 |
Sitnikova T, Roffman J, Santangelo S, Kuperberg G, Goff D. CONTRIBUTIONS OF THE COMT AND MTHFR GENES TO DEFICITS IN ADAPTIVE REAL-WORLD COMPREHENSION IN SCHIZOPHRENIA Schizophrenia Research. 102: 95. DOI: 10.1016/S0920-9964(08)70286-X |
0.476 |
|
| 2008 |
Kuperberg G, Kreher D, Goff D, Swain A, Holt D. SELECTIVE NEURAL DEFICITS IN COMPREHENDING EMOTIONAL INFORMATION WITHIN SOCIAL VIGNETTES IN SCHIZOPHRENIA Schizophrenia Research. 102: 21-22. DOI: 10.1016/S0920-9964(08)70069-0 |
0.407 |
|
| 2007 |
Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, Thompson TR, Volavka J, Webster EL. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. Journal of Clinical Psychopharmacology. 27: 582-9. PMID 18004124 DOI: 10.1097/Jcp.0B013E31815Abf34 |
0.5 |
|
| 2007 |
Freudenreich O, Holt DJ, Cather C, Goff DC. The evaluation and management of patients with first-episode schizophrenia: a selective, clinical review of diagnosis, treatment, and prognosis. Harvard Review of Psychiatry. 15: 189-211. PMID 17924256 DOI: 10.1080/10673220701679804 |
0.442 |
|
| 2007 |
Freudenreich O, Gandhi RT, Walsh JP, Henderson DC, Goff DC. Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics. 48: 405-11. PMID 17878499 DOI: 10.1176/Appi.Psy.48.5.405 |
0.363 |
|
| 2007 |
Goff DC, Newcomer JW. Integrating general health care in private community psychiatry practice. The Journal of Clinical Psychiatry. 68: 49-54. PMID 17685730 DOI: 10.4088/Jcp.0707E19 |
0.306 |
|
| 2007 |
Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. Journal of Clinical Psychopharmacology. 27: 380-6. PMID 17632223 DOI: 10.1097/01.Jcp.0B013E3180Ca86Fa |
0.371 |
|
| 2007 |
Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Expert Review of Neurotherapeutics. 7: 789-796. PMID 17610386 DOI: 10.1586/14737175.7.7.789 |
0.523 |
|
| 2007 |
Kim SY, Appelbaum PS, Swan J, Stroup TS, McEvoy JP, Goff DC, Jeste DV, Lamberti JS, Leibovici A, Caine ED. Determining when impairment constitutes incapacity for informed consent in schizophrenia research. The British Journal of Psychiatry : the Journal of Mental Science. 191: 38-43. PMID 17602123 DOI: 10.1192/Bjp.Bp.106.033324 |
0.449 |
|
| 2007 |
Manoach DS, Ketwaroo GA, Polli FE, Thakkar KN, Barton JJ, Goff DC, Fischl B, Vangel M, Tuch DS. Reduced microstructural integrity of the white matter underlying anterior cingulate cortex is associated with increased saccadic latency in schizophrenia. Neuroimage. 37: 599-610. PMID 17590354 DOI: 10.1016/J.Neuroimage.2007.04.062 |
0.441 |
|
| 2007 |
Fan X, Henderson DC, Chiang E, Briggs LB, Freudenreich O, Evins AE, Cather C, Goff DC. Sexual functioning, psychopathology and quality of life in patients with schizophrenia. Schizophrenia Research. 94: 119-27. PMID 17590315 DOI: 10.1016/J.Schres.2007.04.033 |
0.406 |
|
| 2007 |
Greenzang C, Manoach DS, Goff DC, Barton JJ. Task-switching in schizophrenia: active switching costs and passive carry-over effects in an antisaccade paradigm. Experimental Brain Research. 181: 493-502. PMID 17486327 DOI: 10.1007/S00221-007-0946-8 |
0.469 |
|
| 2007 |
Henderson DC, Cagliero E, Copeland PM, Louie PM, Borba CP, Fan X, Freudenreich O, Goff DC. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. The Journal of Clinical Psychiatry. 68: 533-41. PMID 17474808 DOI: 10.4088/Jcp.V68N0407 |
0.4 |
|
| 2007 |
Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, Henderson DC, Purcell S, Wong DH, Halsted CH, Goff DC. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophrenia Research. 92: 181-8. PMID 17344026 DOI: 10.1016/J.Schres.2007.01.003 |
0.484 |
|
| 2007 |
Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophrenia Research. 92: 90-4. PMID 17321111 DOI: 10.1016/J.Schres.2006.12.030 |
0.515 |
|
| 2007 |
Kuperberg GR, Deckersbach T, Holt DJ, Goff D, West WC. Increased temporal and prefrontal activity in response to semantic associations in schizophrenia. Archives of General Psychiatry. 64: 138-51. PMID 17283282 DOI: 10.1001/Archpsyc.64.2.138 |
0.428 |
|
| 2007 |
Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, Evins AE, Goff DC. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain Acta Psychiatrica Scandinavica. 115: 101-105. PMID 17244173 DOI: 10.1111/J.1600-0447.2006.00855.X |
0.375 |
|
| 2007 |
Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia Psychiatry Research. 149: 267-271. PMID 17112596 DOI: 10.1016/J.Psychres.2006.07.011 |
0.454 |
|
| 2006 |
Weiss AP, Goff D, Schacter DL, Ditman T, Freudenreich O, Henderson D, Heckers S. Fronto-hippocampal function during temporal context monitoring in schizophrenia. Biological Psychiatry. 60: 1268-77. PMID 17020747 DOI: 10.1016/J.Biopsych.2006.06.025 |
0.48 |
|
| 2006 |
Fan X, Anderson EJ, Copeland PM, Borba CP, Nguyen DD, Freudenreich O, Goff DC, Henderson DC. Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic schizophrenia patients. Biological Psychiatry. 60: 1372-7. PMID 16920075 DOI: 10.1016/J.Biopsych.2006.05.006 |
0.375 |
|
| 2006 |
Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research. 86: 15-22. PMID 16884895 DOI: 10.1016/J.Schres.2006.06.026 |
0.468 |
|
| 2006 |
Weiss AP, Henderson DC, Weilburg JB, Goff DC, Meigs JB, Cagliero E, Grant RW. Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatric Services (Washington, D.C.). 57: 1145-52. PMID 16870966 DOI: 10.1176/ps.2006.57.8.1145 |
0.323 |
|
| 2006 |
Kuperberg GR, Kreher DA, Goff D, McGuire PK, David AS. Building up linguistic context in schizophrenia: evidence from self-paced reading. Neuropsychology. 20: 442-52. PMID 16846262 DOI: 10.1037/0894-4105.20.4.442 |
0.417 |
|
| 2006 |
Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. The Journal of Clinical Psychiatry. 67: 789-97. PMID 16841629 DOI: 10.4088/Jcp.V67N0513 |
0.463 |
|
| 2006 |
Henderson DC, Borba CP, Daley TB, Boxill R, Nguyen DD, Culhane MA, Louie P, Cather C, Eden Evins A, Freudenreich O, Taber SM, Goff DC. Dietary intake profile of patients with schizophrenia. Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists. 18: 99-105. PMID 16754415 DOI: 10.1080/10401230600614538 |
0.446 |
|
| 2006 |
Fan X, Liu E, Pristach C, Goff DC, Henderson DC. Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia. Schizophrenia Research. 86: 30-35. PMID 16750348 DOI: 10.1016/J.Schres.2006.04.010 |
0.382 |
|
| 2006 |
Kuperberg GR, Sitnikova T, Goff D, Holcomb PJ. Making sense of sentences in schizophrenia: electrophysiological evidence for abnormal interactions between semantic and syntactic processing. Journal of Abnormal Psychology. 115: 251-65. PMID 16737390 DOI: 10.1037/0021-843X.115.2.251 |
0.39 |
|
| 2006 |
Barton JJ, Goff DC, Manoach DS. The inter-trial effects of stimulus and saccadic direction on prosaccades and antisaccades, in controls and schizophrenia patients. Experimental Brain Research. 174: 487-98. PMID 16642313 DOI: 10.1007/S00221-006-0492-9 |
0.372 |
|
| 2006 |
Roffman JL, Weiss AP, Goff DC, Rauch SL, Weinberger DR. Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia. Harvard Review of Psychiatry. 14: 78-91. PMID 16603474 DOI: 10.1080/10673220600642945 |
0.441 |
|
| 2006 |
Holt DJ, Titone D, Long LS, Goff DC, Cather C, Rauch SL, Judge A, Kuperberg GR. The misattribution of salience in delusional patients with schizophrenia. Schizophrenia Research. 83: 247-56. PMID 16540291 DOI: 10.1016/J.Schres.2005.12.858 |
0.35 |
|
| 2006 |
Couture SM, Roberts DL, Penn DL, Cather C, Otto MW, Goff D. Do baseline client characteristics predict the therapeutic alliance in the treatment of schizophrenia? The Journal of Nervous and Mental Disease. 194: 10-4. PMID 16462549 DOI: 10.1097/01.Nmd.0000195315.39196.52 |
0.417 |
|
| 2006 |
Polli FE, Barton JJ, Vangel M, Goff DC, Iguchi L, Manoach DS. Schizophrenia patients show intact immediate error-related performance adjustments on an antisaccade task. Schizophrenia Research. 82: 191-201. PMID 16448804 DOI: 10.1016/J.Schres.2005.10.003 |
0.433 |
|
| 2006 |
Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, Freudenreich O, Cather C, Evins AE, Goff DC. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatrica Scandinavica. 113: 142-7. PMID 16423166 DOI: 10.1111/J.1600-0447.2005.00612.X |
0.492 |
|
| 2006 |
Henderson DC, Copeland PM, Nguyen DD, Borba CP, Cather C, Eden Evins A, Freudenreich O, Baer L, Goff DC. Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia Acta Psychiatrica Scandinavica. 113: 121-125. PMID 16423163 DOI: 10.1111/J.1600-0447.2005.00621.X |
0.326 |
|
| 2006 |
Holt DJ, Kunkel L, Weiss AP, Goff DC, Wright CI, Shin LM, Rauch SL, Hootnick J, Heckers S. Increased medial temporal lobe activation during the passive viewing of emotional and neutral facial expressions in schizophrenia. Schizophrenia Research. 82: 153-62. PMID 16377154 DOI: 10.1016/J.Schres.2005.09.021 |
0.475 |
|
| 2006 |
Sim K, DeWitt I, Ditman T, Zalesak M, Greenhouse I, Goff D, Weiss AP, Heckers S. Hippocampal and parahippocampal volumes in schizophrenia: a structural MRI study. Schizophrenia Bulletin. 32: 332-40. PMID 16319377 DOI: 10.1093/Schbul/Sbj030 |
0.443 |
|
| 2006 |
Weiss AP, Henderson DC, Weilburg JB, Goff DC, Meigs JB, Cagliero E, Grant RW. Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatric Services. 57: 1145-1152. DOI: 10.1176/Appi.Ps.57.8.1145 |
0.497 |
|
| 2005 |
Goff DC. Pharmacologic implications of neurobiological models of schizophrenia Harvard Review of Psychiatry. 13: 352-359. PMID 16373329 DOI: 10.1080/10673220500433262 |
0.443 |
|
| 2005 |
Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research. 80: 45-53. PMID 16198088 DOI: 10.1016/J.Schres.2005.08.010 |
0.484 |
|
| 2005 |
Evins AE, Deckersbach T, Cather C, Freudenreich O, Culhane MA, Henderson DC, Green MF, Schoenfeld DA, Rigotti NA, Goff DC. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. The Journal of Clinical Psychiatry. 66: 1184-90. PMID 16187778 DOI: 10.4088/Jcp.V66N0915 |
0.448 |
|
| 2005 |
McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research. 80: 19-32. PMID 16137860 DOI: 10.1016/J.Schres.2005.07.014 |
0.485 |
|
| 2005 |
Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research. 80: 9-18. PMID 16125372 DOI: 10.1016/J.Schres.2005.07.015 |
0.431 |
|
| 2005 |
Manoach DS, White N, Lindgren KA, Heckers S, Coleman MJ, Dubal S, Goff DC, Holzman PS. Intact hemispheric specialization for spatial and shape working memory in schizophrenia. Schizophrenia Research. 78: 1-12. PMID 16076549 DOI: 10.1016/J.Schres.2005.06.017 |
0.461 |
|
| 2005 |
Large CH, Webster EL, Goff DC. The potential role of lamotrigine in schizophrenia Psychopharmacology. 181: 415-436. PMID 16001126 DOI: 10.1007/S00213-005-0020-9 |
0.435 |
|
| 2005 |
Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, Nuechterlein KH, Laughren T, Levin R, Stover E, Fenton W, Marder SR. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin. 31: 5-19. PMID 15888422 DOI: 10.1093/Schbul/Sbi020 |
0.404 |
|
| 2005 |
Ongür D, Goff DC. Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophrenia Research. 75: 349-62. PMID 15885526 DOI: 10.1016/J.Schres.2004.08.012 |
0.451 |
|
| 2005 |
Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. Journal of Clinical Psychopharmacology. 25: 218-25. PMID 15876899 DOI: 10.1097/01.Jcp.0000162802.54076.18 |
0.449 |
|
| 2005 |
Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. The American Journal of Psychiatry. 162: 954-62. PMID 15863798 DOI: 10.1176/Appi.Ajp.162.5.954 |
0.345 |
|
| 2005 |
Holt DJ, Weiss AP, Rauch SL, Wright CI, Zalesak M, Goff DC, Ditman T, Welsh RC, Heckers S. Sustained activation of the hippocampus in response to fearful faces in schizophrenia. Biological Psychiatry. 57: 1011-9. PMID 15860342 DOI: 10.1016/J.Biopsych.2005.01.033 |
0.478 |
|
| 2005 |
Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, Cather C, Goff DC. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology. 181: 358-63. PMID 15778880 DOI: 10.1007/S00213-005-2235-1 |
0.509 |
|
| 2005 |
Cather C, Penn D, Otto MW, Yovel I, Mueser KT, Goff DC. A pilot study of functional Cognitive Behavioral Therapy (fCBT) for schizophrenia. Schizophrenia Research. 74: 201-9. PMID 15722000 DOI: 10.1016/J.Schres.2004.05.002 |
0.414 |
|
| 2005 |
Barton JJ, Cherkasova MV, Lindgren KA, Goff DC, Manoach DS. What is perseverated in schizophrenia? Evidence of abnormal response plasticity in the saccadic system. Journal of Abnormal Psychology. 114: 75-84. PMID 15709814 DOI: 10.1037/0021-843X.114.1.75 |
0.455 |
|
| 2005 |
Yurgelun-Todd DA, Coyle JT, Gruber SA, Renshaw PF, Silveri MM, Amico E, Cohen B, Goff DC. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Research. 138: 23-31. PMID 15708298 DOI: 10.1016/J.Pscychresns.2004.11.006 |
0.411 |
|
| 2005 |
Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, Bierer M, Duckworth K, Sacks FM. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. The Journal of Clinical Psychiatry. 66: 183-94; quiz 147, 27. PMID 15705003 DOI: 10.4088/Jcp.V66N0205 |
0.415 |
|
| 2005 |
Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of General Psychiatry. 62: 19-28. PMID 15630069 DOI: 10.1001/Archpsyc.62.1.19 |
0.417 |
|
| 2005 |
Weiss AP, Dewitt I, Goff D, Ditman T, Heckers S. Anterior and posterior hippocampal volumes in schizophrenia. Schizophrenia Research. 73: 103-12. PMID 15567082 DOI: 10.1016/J.Schres.2004.05.018 |
0.488 |
|
| 2005 |
Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology. 179: 144-50. PMID 15502972 DOI: 10.1007/S00213-004-2032-2 |
0.475 |
|
| 2004 |
Manoach DS, Cain MS, Vangel MG, Khurana A, Goff DC, Stickgold R. A failure of sleep-dependent procedural learning in chronic, medicated schizophrenia. Biological Psychiatry. 56: 951-6. PMID 15601605 DOI: 10.1016/J.Biopsych.2004.09.012 |
0.414 |
|
| 2004 |
Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. The Journal of Clinical Psychiatry. 65: 1372-6. PMID 15491241 DOI: 10.4088/Jcp.V65N1012 |
0.424 |
|
| 2004 |
Ramchandran RS, Manoach DS, Cherkasova MV, Lindgren KA, Goff DC, Barton JJ. The relationship of saccadic peak velocity to latency: evidence for a new prosaccadic abnormality in schizophrenia. Experimental Brain Research. 159: 99-107. PMID 15480590 DOI: 10.1007/S00221-004-1940-Z |
0.397 |
|
| 2004 |
Stahl S, Freudenreich O, Goff D. A successful antipsychotic combination trial. Quo Vadis? Acta Psychiatrica Scandinavica. 110: 241-242. PMID 15352924 DOI: 10.1111/J.1600-0447.2004.00370.X |
0.337 |
|
| 2004 |
Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J. Folate, homocysteine, and negative symptoms in schizophrenia American Journal of Psychiatry. 161: 1705-1708. PMID 15337665 DOI: 10.1176/Appi.Ajp.161.9.1705 |
0.468 |
|
| 2004 |
Freudenreich O, Deckersbach T, Goff DC. Insight into current symptoms of schizophrenia. Association with frontal cortical function and affect Acta Psychiatrica Scandinavica. 110: 14-20. PMID 15180775 DOI: 10.1111/J.1600-0447.2004.00319.X |
0.467 |
|
| 2004 |
Goff DC, Freudenreich O. Focus on polypharmacy in schizophrenia: Does anyone truly benefit? International Journal of Neuropsychopharmacology. 7: 109-111. PMID 15137932 DOI: 10.1017/S1461145704004183 |
0.476 |
|
| 2004 |
Evins AE, Cather C, Rigotti NA, Freudenreich O, Henderson DC, Olm-Shipman CM, Goff DC. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. The Journal of Clinical Psychiatry. 65: 307-11; quiz 452-3. PMID 15096068 DOI: 10.4088/Jcp.V65N0304 |
0.347 |
|
| 2004 |
Heckers S, Weiss AP, Deckersbach T, Goff DC, Morecraft RJ, Bush G. Anterior cingulate cortex activation during cognitive interference in schizophrenia. The American Journal of Psychiatry. 161: 707-15. PMID 15056518 DOI: 10.1176/Appi.Ajp.161.4.707 |
0.479 |
|
| 2004 |
Weiss AP, Zalesak M, DeWitt I, Goff D, Kunkel L, Heckers S. Impaired hippocampal function during the detection of novel words in schizophrenia. Biological Psychiatry. 55: 668-75. PMID 15038994 DOI: 10.1016/J.Biopsych.2004.01.004 |
0.487 |
|
| 2004 |
Roberts DL, Penn DL, Cather C, Otto M, Goff DC. Should CBT Target the Social Impairments Associated With Schizophrenia? Journal of Cognitive Psychotherapy. 18: 255-264. DOI: 10.1891/Jcop.18.3.255.65651 |
0.406 |
|
| 2004 |
Cather C, Penn D, Otto M, Goff DC. Cognitive Therapy for Delusions in Schizophrenia: Models, Benefits, and New Approaches Journal of Cognitive Psychotherapy. 18: 207-221. DOI: 10.1891/Jcop.18.3.207.65650 |
0.389 |
|
| 2003 |
Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Annals of the New York Academy of Sciences. 1003: 318-27. PMID 14684455 DOI: 10.1196/Annals.1300.020 |
0.516 |
|
| 2003 |
Lafayette JM, Frankle WG, Pollock A, Dyer K, Goff DC. Clinical characteristics, cognitive functioning, and criminal histories of outpatients with schizophrenia. Psychiatric Services (Washington, D.C.). 54: 1635-40. PMID 14645804 DOI: 10.1176/Appi.Ps.54.12.1635 |
0.439 |
|
| 2003 |
Freudenreich O, Goff DC. Polypharmacy in schizophrenia: a fuzzy concept. The Journal of Clinical Psychiatry. 64: 1132-1132. PMID 14628993 DOI: 10.4088/Jcp.V64N0921D |
0.455 |
|
| 2003 |
Kuperberg GR, Broome MR, McGuire PK, David AS, Eddy M, Ozawa F, Goff D, West WC, Williams SC, van der Kouwe AJ, Salat DH, Dale AM, Fischl B. Regionally localized thinning of the cerebral cortex in schizophrenia. Archives of General Psychiatry. 60: 878-88. PMID 12963669 DOI: 10.1001/Archpsyc.60.9.878 |
0.385 |
|
| 2003 |
Weiss AP, Schacter DL, Goff DC, Rauch SL, Alpert NM, Fischman AJ, Heckers S. Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia. Biological Psychiatry. 53: 48-55. PMID 12513944 DOI: 10.1016/S0006-3223(02)01541-X |
0.487 |
|
| 2003 |
Weiss A, Goff D, Rosen B, DeWitt I, Heckers S. Neural correlates of recognition memory in schizophrenia Schizophrenia Research. 60: 236-237. DOI: 10.1016/S0920-9964(03)81234-3 |
0.444 |
|
| 2003 |
Heckers S, Weiss A, Goff D, Deckersbach T, Bush G. Selective anterior cingulate dysfunction during cognitive interference in schizophrenia Schizophrenia Research. 60: 220. DOI: 10.1016/S0920-9964(03)81185-4 |
0.482 |
|
| 2003 |
Ongur D, Freudenreich O, Henderson DC, Goff DC. Obsessive-compulsive symptoms among people with schizophrenia: Relation to psychotic symptoms, cognitive performance and antipsychotic medications Schizophrenia Research. 60: 23. DOI: 10.1016/S0920-9964(03)80068-3 |
0.478 |
|
| 2002 |
Coyle JT, Tsai G, Goff DC. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Current Drug Targets. Cns and Neurological Disorders. 1: 183-9. PMID 12769626 DOI: 10.2174/1568007024606212 |
0.441 |
|
| 2002 |
Heckers S, Goff D, Weiss AP. Reversed hemispheric asymmetry during simple visual perception in schizophrenia. Psychiatry Research. 116: 25-32. PMID 12426031 DOI: 10.1016/S0925-4927(02)00067-7 |
0.33 |
|
| 2002 |
Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations Acta Psychiatrica Scandinavica. 106: 323-330. PMID 12366465 DOI: 10.1034/J.1600-0447.2002.01331.X |
0.387 |
|
| 2002 |
Weiss AP, Dodson CS, Goff DC, Schacter DL, Heckers S. Intact suppression of increased false recognition in schizophrenia. The American Journal of Psychiatry. 159: 1506-13. PMID 12202270 DOI: 10.1176/Appi.Ajp.159.9.1506 |
0.476 |
|
| 2002 |
Evins AE, Amico E, Posever TA, Toker R, Goff DC. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Research. 56: 19-23. PMID 12084415 DOI: 10.1016/S0920-9964(01)00220-1 |
0.464 |
|
| 2002 |
Pascual-Leone A, Manoach DS, Birnbaum R, Goff DC. Motor cortical excitability in schizophrenia. Biological Psychiatry. 52: 24-31. PMID 12079727 DOI: 10.1016/S0006-3223(02)01317-3 |
0.4 |
|
| 2002 |
Goff DC. A 23-year-old man with schizophrenia Journal of the American Medical Association. 287: 3249-3257. PMID 12076222 DOI: 10.1001/Jama.287.24.3249 |
0.37 |
|
| 2002 |
Manoach DS, Lindgren KA, Cherkasova MV, Goff DC, Halpern EF, Intriligator J, Barton JJ. Schizophrenic subjects show deficient inhibition but intact task switching on saccadic tasks. Biological Psychiatry. 51: 816-26. PMID 12007456 DOI: 10.1016/S0006-3223(01)01356-7 |
0.373 |
|
| 2002 |
Barton JJ, Cherkasova MV, Lindgren K, Goff DC, Intriligator JM, Manoach DS. Antisaccades and task switching: studies of control processes in saccadic function in normal subjects and schizophrenic patients. Annals of the New York Academy of Sciences. 956: 250-63. PMID 11960809 DOI: 10.1111/J.1749-6632.2002.Tb02824.X |
0.332 |
|
| 2002 |
Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biological Psychiatry. 51: 493-7. PMID 11922885 DOI: 10.1016/S0006-3223(01)01321-X |
0.403 |
|
| 2001 |
Goff DC, Freudenreich O, Evins AE. Augmentation strategies in the treatment of schizophrenia. Cns Spectrums. 6: 904-911. PMID 15328472 DOI: 10.1017/S1092852900000961 |
0.46 |
|
| 2001 |
Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. Journal of Clinical Psychopharmacology. 21: 484-7. PMID 11593073 DOI: 10.1097/00004714-200110000-00005 |
0.443 |
|
| 2001 |
Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. The American Journal of Psychiatry. 158: 1367-77. PMID 11532718 DOI: 10.1176/Appi.Ajp.158.9.1367 |
0.531 |
|
| 2001 |
Manoach DS, Halpern EF, Kramer TS, Chang Y, Goff DC, Rauch SL, Kennedy DN, Gollub RL. Test-retest reliability of a functional MRI working memory paradigm in normal and schizophrenic subjects. The American Journal of Psychiatry. 158: 955-8. PMID 11384907 DOI: 10.1176/Appi.Ajp.158.6.955 |
0.326 |
|
| 2001 |
Gould RA, Mueser KT, Bolton E, Mays V, Goff D. Cognitive therapy for psychosis in schizophrenia: an effect size analysis. Schizophrenia Research. 48: 335-42. PMID 11295385 DOI: 10.1016/S0920-9964(00)00145-6 |
0.486 |
|
| 2001 |
Frankle WG, Shera D, Berger-Hershkowitz H, Evins AE, Connolly C, Goff DC, Henderson DC. Clozapine-Associated Reduction in Arrest Rates of Psychotic Patients With Criminal Histories American Journal of Psychiatry. 158: 270-274. PMID 11156810 DOI: 10.1176/Appi.Ajp.158.2.270 |
0.369 |
|
| 2000 |
Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone-associated hyperprolactinemia. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 6: 425-9. PMID 11155212 DOI: 10.4158/Ep.6.6.425 |
0.337 |
|
| 2000 |
Heckers S, Curran T, Goff D, Rauch SL, Fischman AJ, Alpert NM, Schacter DL. Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia. Biological Psychiatry. 48: 651-7. PMID 11032976 DOI: 10.1016/S0006-3223(00)00919-7 |
0.463 |
|
| 2000 |
Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E, Saper CB, Rauch SL. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biological Psychiatry. 48: 99-109. PMID 10903406 DOI: 10.1016/S0006-3223(00)00227-4 |
0.384 |
|
| 2000 |
Hofmann SG, Bufka LF, Brady SM, Rand CD, Goff DC. Cognitive-Behavioral Treatment of Panic in Patients with Schizophrenia: Preliminary Findings Journal of Cognitive Psychotherapy. 14: 381-392. DOI: 10.1891/0889-8391.14.4.381 |
0.432 |
|
| 1999 |
Heckers S, Goff D, Schacter DL, Savage CR, Fischman AJ, Alpert NM, Rauch SL. Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. Archives of General Psychiatry. 56: 1117-23. PMID 10591289 DOI: 10.1001/Archpsyc.56.12.1117 |
0.484 |
|
| 1999 |
Manoach DS, Press DZ, Thangaraj V, Searl MM, Goff DC, Halpern E, Saper CB, Warach S. Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biological Psychiatry. 45: 1128-37. PMID 10331104 DOI: 10.1016/S0006-3223(98)00318-7 |
0.348 |
|
| 1999 |
Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biological Psychiatry. 45: 512-514. PMID 10071726 DOI: 10.1016/S0006-3223(98)00367-9 |
0.448 |
|
| 1999 |
Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry. 56: 21-7. PMID 9892252 DOI: 10.1001/Archpsyc.56.1.21 |
0.415 |
|
| 1999 |
Goff DC, Bagnell AL, Perlis RH. Glutamatergic Augmentation Strategies for Cognitive Impairment in Schizophrenia Psychiatric Annals. 29: 649-654. DOI: 10.3928/0048-5713-19991101-11 |
0.478 |
|
| 1998 |
Goff DC, Evins AE. Negative symptoms in Schizophrenia: Neurobiological models and treatment response Harvard Review of Psychiatry. 6: 59-77. PMID 10370450 DOI: 10.3109/10673229809000313 |
0.404 |
|
| 1998 |
Heckers S, Rauch SL, Goff D, Savage CR, Schacter DL, Fischman AJ, Alpert NM. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nature Neuroscience. 1: 318-23. PMID 10195166 DOI: 10.1038/1137 |
0.452 |
|
| 1998 |
Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia : Safety, clinical efficacy, and predictors of response The Journal of Clinical Psychiatry. 59: 585-588. PMID 9862604 DOI: 10.4088/Jcp.V59N1105 |
0.428 |
|
| 1998 |
Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. The American Journal of Psychiatry. 155: 1207-13. PMID 9734544 DOI: 10.1176/Ajp.155.9.1207 |
0.357 |
|
| 1998 |
Magharious W, Goff DC, Amico E. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Research-Neuroimaging. 77: 159-166. PMID 9707298 DOI: 10.1016/S0165-1781(97)00137-6 |
0.314 |
|
| 1997 |
Evins AE, Amico ET, Shih V, Goff DC. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics Journal of Neural Transmission. 104: 761-766. PMID 9444574 DOI: 10.1007/Bf01291892 |
0.392 |
|
| 1997 |
Goff DC, Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophrenia Research. 27: 157-68. PMID 9416645 DOI: 10.1016/S0920-9964(97)00079-0 |
0.502 |
|
| 1996 |
Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. The American Journal of Psychiatry. 153: 1628-30. PMID 8942463 DOI: 10.1176/Ajp.153.12.1628 |
0.401 |
|
| 1996 |
Evins AE, Goff DC. Adjunctive Antidepressant Drug Therapies in the Treatment of Negative Symptoms of Schizophrenia Cns Drugs. 6: 130-147. DOI: 10.2165/00023210-199606020-00005 |
0.458 |
|
| 1996 |
Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC. Erythromycin-induced clozapine toxic reaction. Jama Internal Medicine. 156: 675-677. DOI: 10.1001/Archinte.1996.00440060103013 |
0.405 |
|
| 1995 |
Goff DC, Tsai G, Beal MF, Coyle JT. Tardive dyskinesia and substrates of energy metabolism in CSF. The American Journal of Psychiatry. 152: 1730-6. PMID 8526238 DOI: 10.1176/Ajp.152.12.1730 |
0.314 |
|
| 1995 |
Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. The American Journal of Psychiatry. 152: 1213-5. PMID 7625475 DOI: 10.1176/Ajp.152.8.1213 |
0.444 |
|
| 1995 |
Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology. 117: 417-23. PMID 7604142 DOI: 10.1007/Bf02246213 |
0.408 |
|
| 1993 |
Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA. A Placebo-Controlled Trial of Selegiline (L-Deprenyl) in the Treatment of Tardive Dyskinesia Biological Psychiatry. 33: 700-706. PMID 8102552 DOI: 10.1016/0006-3223(93)90119-X |
0.35 |
|
| 1992 |
Goff DC, Olin JA, Jenike MA, Baer L, Buttolph ML. Dissociative symptoms in patients with obsessive-compulsive disorder. Journal of Nervous and Mental Disease. 180: 332-337. PMID 1583477 DOI: 10.1097/00005053-199205000-00008 |
0.305 |
|
| 1991 |
McCormick S, Goff DC. Apparent decrease in schizophrenia [2] British Journal of Psychiatry. 159: 725. PMID 1756356 DOI: 10.1192/Bjp.159.5.725A |
0.526 |
|
| 1991 |
Goff DC, Midha KK, Brotman AW, Mccormick S, Waites M, Amico ET. An open trial of buspirone added to neuroleptics in schizophrenic patients Journal of Clinical Psychopharmacology. 11: 193-197. DOI: 10.1097/00004714-199106000-00008 |
0.334 |
|
| 1986 |
Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, Black B, Shader RI. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? American Journal of Psychiatry. 143: 650-651. PMID 3963258 DOI: 10.1176/Ajp.143.5.650 |
0.319 |
|
| Show low-probability matches. |